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Neoplasia was initiated 6 years ago with the vision of
providing a journal for fair-minded, constructive, and
prompt review of manuscripts, which would provide the
scientific community a platform for the rapid dissemina-
tion of basic and clinical findings in cancer research.
During this time, Neoplasia has provided authors with a
real-time, password-protected web-based peer review
system, which provided critiques of each individual re-
viewer in real time. This novel approach to peer review
has provided authors with the ability to post their
responses to the reviewer’s comments in a point-by-point
format prior to the editorial decision. This approach
allowed the Editorial Office to obtain information from
both the reviewers and authors, thereby providing the
editor with additional information to make editorial deci-
sions. This approach provided for a much faster and
more fair-minded decision-making process, as well as
reduced the overall turnaround time for manuscript
revisions.
The overall impact and acceptance of Neoplasia by the
scientific community has been heartwarming and can be
quantified by several parameters. Firstly, over the past 3
years, there has been consistent, broad-based publication
of articles from diverse areas of cancer research. This is
best shown by Table 1, which lists articles by general topic
areas for publication years 2002–2004, where the number
of papers in clinical investigations and angiogenesis has
increased steadily over this period. A second parameter
from which to judge the impact of a journal is in the growth of
the number of manuscript submissions. In 2004, the num-
ber of articles submitted to Neoplasia increased by 40%
over the previous year. This is a truly remarkable statistic
and required the publisher to increase the number of pages
published in 2004 and also resulted in the necessity of
increasing the publication frequency of Neoplasia from its
current bimonthly rate to monthly for Volume 7 in 2005.
Significant changes for Neoplasia in 2005 will be a rapid
listing of accepted articles on the PubMed/Medline data-
base. This will provide authors who publish in Neoplasia
with the most rapid dissemination of their results to other
scientists, thereby fulfilling one of the most important mis-
sions of Neoplasia.
On behalf of the Editorial Office, members of the Editorial
Board, and Publisher, BC Decker, we wish to thank all
participants for embracing Neoplasia as a conduit for pub-
lishing their important research findings. We welcome any
feedback and comments from which we can continually
improve the role of Neoplasia in facilitating the timely
distribution of your vitally important research results.
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Table 1. Major Topics of Publications in Neoplasia From 2002 to 2004.
Subject 2002 2003 2004
Apoptosis 38, 62 5, 21, 70
Cancer genetics 3, 9, 12, 14, 16, 22, 23, 30, 32,
33, 40, 46, 47, 48, 59, 61
4, 6, 7, 12, 19, 22, 25, 26, 36,
38, 39, 41, 42, 45
1, 4, 9, 13, 15, 17, 20, 22, 26,
28, 44, 48, 49, 52, 56, 59, 66, 71
Cell and tumor biology 4, 7, 15, 17, 19, 20, 21, 24, 27,
36, 42, 44, 45, 54, 57
8, 10, 11, 13, 14, 23, 24, 29,
34, 43, 46, 54
3, 6, 7, 18, 19, 25, 29, 30, 31,
35, 36, 45, 60, 61, 65
Experimental therapeutics 5, 6, 8, 10, 11, 18, 26, 34, 35,
37, 43, 50, 52
1, 2, 3, 16, 18, 31, 37, 44, 47,
48, 50, 52, 58
2, 12, 37, 38, 51, 53, 54, 62, 63, 64
Tumor immunology 1 69
Epidemiology and prevention 9, 28
Cancer imaging 25, 28, 29, 39, 53, 56, 58, 60 15, 21, 27, 33, 35, 40, 53, 56, 57 8, 10, 14, 16, 23, 24, 40, 47
Clinical investigations 49, 51 20, 30, 49, 51 32, 33, 41, 42, 46, 55, 57, 58, 67, 68
Endocrinology 2
Animal models 13, 31, 55 55 11, 34
Angiogenesis 41 17, 32 27, 39, 43, 49, 50
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